anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tobacco use is the greatest cause of preventable death in the US and cigarette smokers exhibit substantial relapse following treatment. Understanding the brain mechanisms involved in tobacco dependence is an important step toward reducing the high rate of relapse associated with current behavioral and pharmacological treatments for smoking cessation. This study seeks to examine the effects of high frequency, repetitive Transcranial Magnetic Stimulation (rTMS) on decision-making and smoking behavior. A concept central to this study is that "quitting" tobacco necessitates making conscious choices not to smoke (to delay gratification) and these choices are influenced by the balance of activity between the frontal-parietal systems that process the value of rewards and limbic systems that are involved with immediate gratification. We aim to: 1) determine how two different levels of cortical excitation (10 Hz and 20Hz), induced by different rTMS frequencies, influence reward and risk-taking choices and cigarette consumption. Additionally, we aim to 2) determine how limbic activation due to acute nicotine withdrawal and/or satiation modifies the effects in aim 1. Twenty non-smoking and 20 smoking participants will receive two levels of high frequency rTMS and comparable sham stimulation (using electrical scalp stimulation) delivered over the left prefrontal cortex. Smokers will also crossover between nicotine satiation and acute withdrawal conditions to determine how rTMS interacts with limbic activation associated with nicotine use and withdrawal. In addition, changes in preattentional (brainstem-thalamus processing as measured using the P50 midlatency auditory evoked potential) and attentional (thalamocortical processing as measured using the Psychomotor Vigilance Task; PVT) will be assessed before and after treatment to quantitatively determine changes in preattentional/arousal and attentional function.
FIELD: organic chemistry, peptides, pharmacy. SUBSTANCE: invention relates to the novel compound peptide of the general formula: Thr-Gly-Glu-Asn- His-Arg eliciting biological activity in inducing differentiation and inhibition of proliferation of cancer tumors and activity of protective and normalizing effect with respect to vitality processes of mammalian cells. Peptide is prepared by method of solid-phase synthesis by successive elongation of peptide chain and showing the following properties: molecular mass is 714 ± 1 Da; isoelectric point at 7.18; pH stability in the range of pH from 2.0 to 9.0; thermal stability in the range of temperature from 0 to +50 C; homogenicity is 99.8%. Peptide is soluble in water, physiological solutions and buffer solutions with pH = 2.0-9.0, it has no immunogenicity and toxicity. Invention relates also to pharmaceutical composition containing indicated peptide taken in the effective dose as an active component. EFFECT: valuable medicinal properties of peptide and composition. 2 cl, 9 dwg,, 4 ex
NEW MATERIAL:An imidazole compound expressed by formula I (R represents H or alkyl). EXAMPLE:1-Dodecyl-2-ethylimidazole hydrochloride. USE:An acidic antimold, antifungal agent, etc., soluble in water, ethanol, methanol and acetone. PREPARATION:1mol imidazole compound expressed by formula II, 1mol triethylamine and 1mol dodecyl bromide are heated at 40-60 deg.C in a solvent such as methanol and the solvent is distilled off under reduced pressure therefrom. An appropriate amount of water is added thereto and the resultant product is extracted with a solvent such as chloroform and dried with anhydrous Na2CO3. The residue is then subjected to silica gel chromatography, separated, purified and crystallized by adding a solvent, e.g. hydrochloric acid, ethanol, etc., thereto to obtain the aimed white crystal compound expressed by formula I.
This Treatment Protocol will offer patients access to aerosolized Infasurf therapy at the time RDS is diagnosed if a patient is \<12 hours of age and has not previously received liquid surfactant, or is \<24 hours of age, and received liquid surfactant in the first hour after birth, was extubated and RDS is worsening. Parents must give informed consent. Up to 2 repeat doses of aerosolized Infasurf can be administered. Aerosolized Infasurf must be administered as described in the protocol. Adverse events at administration (if any) and all serious adverse events related or possibly related the aerosolized Infasurf therapy will be extracted from the medical record and reported to the sponsor, ONY Biotech. A copy of the discharge summary of patients will be collected by the sponsor using HIPAA compliant methodology for generation of a data set that will characterize adverse events and other efficacy and safety data.
Minimally invasive (endoscopic) transversus abdominis release (TAR) - new technique for the treatment of patients with large incisional ventral hernia. Term "endoscopic" TAR combines two minimally invasive (laparosopic or extraperitoneal (eTEP) approaches. These techniques have demonstrated significant advantages compared with open TAR in several retrospective studies. There are currently no randomized trials comparing open and endoscopic TAR operations for incisional ventral hernia repair.This study aims to comparatively evaluate the early and long-term results of open and endoscopic TAR procedure for large midline incisional ventral hernias.

The sample size was determined based on a previously conducted retrospective pilot study comparing the results of open and endoscopic TAR procedures for midline incisional ventral hernia repair. The retrospective study included 133 patients with midline incisional ventral hernias who were underwent Rives-Stoppa hernia repair in combination with bilateral posterior component separation with transversus abdominis release via open (open TAR) or endoscopic (eTAR) technique in Moscow City Hospital №1 from January 2018 to December 2022. All patients were included in the study, starting from the moment of endoscopic TAR technique was introduced into the clinic. At the same time, the learning curve for the open TAR had already been reached at that time; more than 20 open TAR interventions were performed in the clinic in 2016-2017. The average hospitalization time in open TAR group was 6.7 ± 2.14 days. In endoscopic TAR group the average hospitalization time after surgery was 5.2 ± 1.65 bed days. After achieving the learning curve (20 operations) for the endoscopic TAR procedure technique average hospitalization period after surgery was 4.8 ± 1.47 days. Thus, a decrease in the duration of hospitalization in endoscopic TAR group after reaching the learning curve was noted by 28.4%. This fact, based on a retrospective pilot study, allows the investigators to assume as a hypothesis for this RCT a reduction in the duration of hospitalization during endoscopic TAR by at least 30% as a guideline for calculating the power of the study. Thus, assuming a Type I error probability α of 0.05 and a Type 2 error probability β of 0.20, it would require a total sample size of 36 patients (18 patients in each group).
Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration. Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose. The total body clearance is 0.96 mL/min/kg and the renal clearance is 0.6 mL/min/kg. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption. The metabolite ucb L057 is excreted by glomerular filtration and active tubular secretion with a renal clearance of 4 mL/min/kg. Levetiracetam elimination is correlated to creatinine clearance. Levetiracetam clearance is reduced in patients with impaired renal function (see Special Populations, Renal Impairment and DOSAGE AND ADMINISTRATION, Adult Patients with Impaired Renal Function).
This survey study is follow-up to a survey carried out in 2014, addressed to Swedish General Dental Practitioners (GDPs) and Specialist Paediatric Dentists (SPDs). The aim of this study is to investigate Swedish dentists' attitudes about pain management when treating children and adolescents by assessing 1) dentists' recommendations for the use of pre- and postoperative analgesics, 2) use of local anaesthesia during treatment of primary and permanent teeth, and 3) if the use of these strategies differs between GDPs and SPDs.

All SPDs (including post-graduate dentists in paediatric dentistry) in Sweden, circa 150 in total, and approximately 1,000 GDPs, will be invited to answer the questionnaire. To be included GDPs need to have registered addresses in county Skåne, Sweden, and be accredited to provide dental care to children and adolescents by Region Skåne, the regional public health and dental care provider. A questionnaire along with written information about the study and two consent forms will be mailed to presumptive study participants. Those willing to participate in the study are asked to return (postage prepaid) one signed consent form and the completed questionnaire. The questionnaire is adapted from one previously used in Sweden. It contains demographic questions, and questions regarding work situation. These questions are followed by four clinical scenarios, and questions relating to use of pain management practices. Responses are given on a 5-point Likert scale. The final questions are open ended and concern the use of pre- and postoperative analgesics.
Meta-analysis was used to analyze the efficacy of conventional western medicine plus Buyanghuanwu Decoction in the treatment of convalescent patients with stroke, and to observe its influence on the neurological function and condition of patients. According to the research direction and set keywords, the research literature was retrieved from Wanfang Medical Science, CNKI, VIP, PubMed and other domestic and foreign literature databases. A total of 13 articles with 1023 patients were included in this meta-analysis, with a large sample size. Outcome measures of the meta-analysis included efficacy, National Institutes of Health Stroke Scale (NIHSS) score, Barthel Index Rating Scale (BI) score, C-reactive protein (CRP) and homocysteine (Hcy) score. Compared with western medicine group, the increase of BI score and the decrease of NIHSS score, CRP and Hcy in combined medicine group were greater (P < .05). Conventional Western medicine combined with Buyang Huanwu Decoction can improve the rehabilitation effect, living ability and neurological function of patients with stroke, and reducing the inflammatory response, it is beneficial to create favorable conditions for patients' rehabilitation and improve prognosis, which is worthy of clinical application. The effect of this protocol on long-term survival of patients can be further analyzed in the future.
Internet-based stepped care comprises interactive support (Step 1) and Cognitive Behavioral Therapy (CBT; Step 2). Step 1 starts directly after randomization and extends over a 24 months period. Step 2 extends to a period of ten weeks.
Bifunctional antibiotics that target both bacterial RNA and resistance-causing enzymes are disclosed. The A-site of bacterial 16S rRNA serves as the target site for most aminoglycoside antibiotics. Resistance to this class of antibiotics is frequently developed by microbial enzymatic acetylation, phosphorylation or ribosylation of aminoglycosides, modifications that weaken their interactions with the target RNA. Using surface plasmon resonance (SPR), the binding affinity and stoichiometry of various amino-glycosides have been investigated and it was found that neamine, the key pharmacophore of the deoxystreptamine class of amino-glycosides, binds to the A-site in a two to one stoichiometry with a K d  of 10 μM for each binding site. A library of neamine dimers was prepared and their affinities to 16S rRNA A-site were determined by SPR, with K d =40 nM for the best dimer (an ˜10 3 -fold increase in affinity). Antibiotic activities of the dimers were determined for several bacterial strains by the Kirby-Bauer method. The most active dimer, based on antibiotic activity, also showed the highest inhibition of in vitro translation (IC 50 =0.055 μM). The latter assay was developed in order to correlate the relationship between SPR-based affinity and translation inhibition. By these combined methods, transport limitations for the semisynthetic aminoglycosides as well as non-ribosomally based antibiotic activity could be determined. Further analysis of these dimers as substrates for aminoglycoside modifying-enzymes identified a neamine dimer that was a potent inhibitor (K is =0.1 μM) of the APH(2″) activity of the bifunctional enzyme AAC(6″)-APH(2″), the primary enzyme responsible for high level gentamicin C resistance in several bacterial strains.
Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects.
Vitamin D insufficiency is common in CF patients. Treatment of vitamin D insufficiency in CF patients requires large doses of vitamin D. Adequate vitamin D status in CF is important for skeletal health and the prevention of osteoporosis. In addition to skeletal benefits of vitamin D, recent evidence has demonstrated that vitamin D plays an important role in the regulation of the immune system by increasing anti-microbial peptides in the lung and other barrier sites. Whether improving vitamin D status in CF patients would enhance the immune system has not yet been explored in a clinical study. This would have significant clinical impact in CF care since vitamin D status remains undertreated, especially in the setting of infection. The hypothesis of this proposal is that rapid correction of vitamin D insufficiency will result in improved innate immunity by increasing production of anti-microbial peptides resulting in more effective killing of bacteria. To address our hypothesis, the following two aims are proposed: 1) To evaluate the effect of rapid correction of vitamin D insufficiency as an adjunctive therapy on production of anti-microbial peptides in acute respiratory exacerbation in CF patients 2) To determine the effect of vitamin D treatment on bacterial killing in acute respiratory exacerbation in CF patients and to correlate with free LL-37 levels in sputum. The long term objective of this proposal and of our research group is to study the role of nutrition including vitamin D to improve the immune system in the setting of infection in CF.
Lithium levels should be closely monitored when patients initiate or discontinue NSAID use. In some cases, lithium toxicity has resulted from interactions between an NSAID and lithium. Indomethacin and piroxicam have been reported to increase significantly steady-state plasma lithium concentrations. There is also evidence that other nonsteroidal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect. In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with celecoxib 200 mg BID as compared to subjects receiving lithium alone.

Lithium may impair mental and/or physical abilities. Patients should be cautioned about activities requiring alertness (e.g., operating vehicles or machinery).
Flutamide 250 mg taken by mouth twice a day for 4 weeks. Flutamide is an androgen-receptor blocker.
The COVID-19 pandemic, triggered by severe acute respiratory syndrome coronavirus 2, has affected millions of people worldwide. Much research has been dedicated to our understanding of COVID-19 disease heterogeneity and severity, but less is known about recovery associated changes. To address this gap in knowledge, we quantified the proteome from serum samples from 29 COVID-19 convalescents and 29 age-, race-, and sex-matched healthy controls. Samples were acquired within the first months of the pandemic. Many proteins from pathways known to change during acute COVID-19 illness, such as from the complement cascade, coagulation system, inflammation and adaptive immune system, had returned to levels seen in healthy controls. In comparison, we identified 22 and 15 proteins with significantly elevated and lowered levels, respectively, amongst COVID-19 convalescents compared to healthy controls. Some of the changes were similar to those observed for the acute phase of the disease, i.e. elevated levels of proteins from hemolysis, the adaptive immune systems, and inflammation. In contrast, some alterations opposed those in the acute phase, e.g. elevated levels of CETP and APOA1 which function in lipid/cholesterol metabolism, and decreased levels of proteins from the complement cascade (e.g. C1R, C1S, and VWF), the coagulation system (e.g. THBS1 and VWF), and the regulation of the actin cytoskeleton (e.g. PFN1 and CFL1) amongst COVID-19 convalescents. We speculate that some of these shifts might originate from a transient decrease in platelet counts upon recovery from the disease. Finally, we observed race-specific changes, e.g. with respect to immunoglobulins and proteins related to cholesterol metabolism.
A surgical support system, a surgical support method, and an information storage medium are provided, which can efficiently support information for a plurality of team members. The surgical support system (50) includes a processor (211). The processor (211) is connected to the terminal in a communication manner, and performs processing for displaying a display screen on the terminal, thereby presenting the display screen to a member other than a surgeon (294) among the members of the operation team via the terminal. The display contains a live image area and an auxiliary area. The live image area displays a live image of a procedure performed by a member of the procedure team. The support area displays information on a support job selected by a selection input by a member via a terminal among a plurality of support jobs for managing a surgery.
A single dose two way crossover bioequivalence study in 40 normal healthy males and females was utilized to evaluate the pharmacokinetics and bioequivalence of Risperidone ODT (orally dissolving tablet) formulations. The test product was a 1 mg ODT tablet formulation of Risperidone manufactured by Ranbaxy Laboratories Ltd. The reference product was commercially available Risperidone 1 mg ODT tablets (Risperdal®), Janssen Pharmaceutica Products, LP. Each single oral dose (1 mg) will be administered orally as a 1 mg tablet. Blood samples were collected at intervals over a 72-hour period after medication administration. There was a washout period of 14 days between the two periods of the study.
PURPOSE:To detect exactly the antibody in a sample to be inspected by an enzyme immunological measurement method, etc. in the stage of using an antigen associated to the adult T cell leukemia (ATL) to measure an ATL virus antibody by using the sample prepd. by adding the ATL virus antigen to the sample to be examined as a contrast sample. CONSTITUTION:The antigen associated to ATL obtd. by treating the MT-2 cell obtd. by the mixed culture with the leukemia cell sampled from the peripheral blood of an ATL patient with a surface active agent is conjugated at a substantial amt. to the inside surface of a cup for immunological measurement. A specified amt. of the ATL virus antigen obtd. from the MT- 2 cell cultured liquid and the serum to be inspected is added to one group (b) of the cup. Only the serum to be inspected is added to the other one group (a) and only the serum of the normal rabbit to be used for dilution of the serum to be inspected or the ATL virus antigen is added to another one group (c). After the respective groups are incubated, the ATL virus antibody labeled by enzyme, radioactivity, etc. is added to the cup to effect a reaction and then to effect the reaction of enzyme with a substrate. The coloration and radioactivity, etc. after specified time are measured and the coloration and radioactivity of the cup groups (a), (b), (c) with the substrate are measured. The rate of inhibition expressed by the formula is calculated from the measured values A, B, C thereof, and >=50% rate of inhibition is determined as antibody positive and <=50% rate as negative.
Patients will receive erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be switched to the combination arm. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study.
FIELD: medicine, surgery. SUBSTANCE: a napkin is used with immobilized trypsin and decametoxin. A napkin is impregnated with the solution of "photosens" photosensitizer at concentration of 125-5000 mcg/ml to be kept on an ulcer for 24 h. Ulcer is treated with NO- containing air-plasmatic flows at impact duration of 10-15 sec for 1cm 2 . Irradiation of wound is carried out with light at 670 nm wave length followed by daily impact of NO-containing air- plasmatic flows upon a wound at the same impact duration values. The method enables to accelerate ulcerous purification against necrotic tissues, pathogenic microflora and stimulate tissue regeneration. EFFECT: higher efficiency of therapy. 2 ex, 1 tbl